Sponsor pipeline

Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company clinical trial pipeline

Get alerts when Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company's trials change

1 active trials 1 recruiting 1 disease areas 8 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-11

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 1 with a notable change, 0 with minor changes only.

  1. Notable

    Primary completion pushed from Oct 15, 2026 to Jun 2027

    Also in this update: Primary endpoint(s) modified; Sponsor changed: Ajax Therapeutics, Inc. to Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; and 1 more change in the last 30 days

    Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyPhase 1 NCT06343805 Registry history

    Updated

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 1
1

Active trials

NCT IDTitleConditionStatusUpdated
Phase 1
NCT06343805 A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF)… Primary Myelofibrosis Recruiting 2026-10-09

Disease areas by active trials

Myelofibrosis (1)

Get alerts when Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free